These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 27987645)

  • 1. Health Economics as Rhetoric: The Limited Impact of Health Economics on Funding Decisions in Four European Countries.
    Franken M; Heintz E; Gerber-Grote A; Raftery J
    Value Health; 2016 Dec; 19(8):951-956. PubMed ID: 27987645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twenty years of using economic evaluations for drug reimbursement decisions: what has been achieved?
    Drummond M
    J Health Polit Policy Law; 2013 Dec; 38(6):1081-102. PubMed ID: 23974475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finding legitimacy for the role of budget impact in drug reimbursement decisions.
    Niezen MG; de Bont A; Busschbach JJ; Cohen JP; Stolk EA
    Int J Technol Assess Health Care; 2009 Jan; 25(1):49-55. PubMed ID: 19126251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health economic evaluation in England.
    Raftery J
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):367-74. PubMed ID: 25444294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reimbursement of targeted cancer therapies within 3 different European health care systems.
    Mihajlović J; Dolk C; Tolley K; Simoens S; Postma MJ
    Clin Ther; 2015 Feb; 37(2):474-80. PubMed ID: 25638534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and Bangladesh.
    Teerawattananon Y; Tantivess S; Yamabhai I; Tritasavit N; Walker DG; Cohen JT; Neumann PJ
    Health Res Policy Syst; 2016 Dec; 14(1):86. PubMed ID: 27912780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
    Barbieri M; Drummond M; Willke R; Chancellor J; Jolain B; Towse A
    Value Health; 2005; 8(1):10-23. PubMed ID: 15841890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of Change in the Cost-effectiveness Threshold.
    Paulden M; O'Mahony J; McCabe C
    Med Decis Making; 2017 Feb; 37(2):264-276. PubMed ID: 27553208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System.
    Hasegawa M; Komoto S; Shiroiwa T; Fukuda T
    Value Health; 2020 Jan; 23(1):43-51. PubMed ID: 31952673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rationing in German health care with particular consideration of oncology: view points of German stakeholders--a qualitative interview study].
    Lange J; Gönner C; Vollmann J; Rauprich O
    Gesundheitswesen; 2015 Jan; 77(1):8-15. PubMed ID: 24696371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can economic evaluation guidelines improve efficiency in resource allocation? The cases of Portugal, The Netherlands, Finland, and the United Kingdom.
    Kanavos P; Trueman P; Bosilevac A
    Int J Technol Assess Health Care; 2000; 16(4):1179-92. PubMed ID: 11155837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?
    Oliva-Moreno J; Puig-Junoy J; Trapero-Bertran M; Epstein D; Pinyol C; Sacristán JA
    Value Health; 2020 Jan; 23(1):25-31. PubMed ID: 31952669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconciliation of economic concerns and health policy: illustration of an equity adjustment procedure using proportional shortfall.
    Stolk EA; van Donselaar G; Brouwer WB; Busschbach JJ
    Pharmacoeconomics; 2004; 22(17):1097-107. PubMed ID: 15612829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer.
    Garrison LP; Veenstra DL
    Value Health; 2009; 12(8):1118-23. PubMed ID: 19624617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health economic studies: an introduction to cost-benefit, cost-effectiveness, and cost-utility analyses.
    Angevine PD; Berven S
    Spine (Phila Pa 1976); 2014 Oct; 39(22 Suppl 1):S9-15. PubMed ID: 25299265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation: what does a nurse manager need to know?
    Douglas HR; Normand C
    J Nurs Manag; 2005 Sep; 13(5):419-27. PubMed ID: 16108780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
    Bryan S; Williams I; McIver S
    Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.